Developing CAR-T/NK cells that target EphA2 for non-small cell lung cancer treatment
The findings of this study highlight the potential of CAR-T/NK cell therapy targeting EphA2 as an effective treatment for lung cancer, particularly NSCLC with high EphA2 expression. By leveraging the specific targeting capabilities of CAR-T cells and the unique properties of CAR-NK cells, this approach provides a promising therapeutic strategy to address the unmet needs in NSCLC treatment.
Authors
- Jin Tae Hong
- S. Kim (ORCID: https://orcid.org/0009-0000-8976-2455)
- Tae‐Don Kim (ORCID: https://orcid.org/0000-0002-5910-4264)
- Soo Yun Lee
- Seona Jo
- Hyo-Young Chung
- Jae Hyun Bae (ORCID: https://orcid.org/0000-0002-1384-6123)
- Seok‐min Kim (ORCID: https://orcid.org/0000-0002-1609-6786)
- Ji Hyun Kim (ORCID: https://orcid.org/0000-0001-8477-0157)
Institutions
- Chungbuk National University (KR)
- Osong Medical Innovation Foundation (KR)
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Korea University of Science and Technology (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1448438
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.23